Pfizer posted their third-quarter financial results before the opening bell on Tuesday. The pharmaceutical giant beat Wall Street estimates.
Pfizer reported total revenue of $24.10 billion in Q3 vs. $21.09 billion expected. Earnings per share at $1.34 a share vs. $1.03 a share estimate.
Dr. Albert Bourla, Chairman and Chief Executive Officer, commented on the latest financial results: ”While we are proud of our third quarter financial performance, we are even more proud of what these financial results represent in terms of the positive impact we are having on human lives around the world. For example, more than 75% of the revenues we have recorded up through third-quarter 2021 for Comirnaty* have come from supplying countries outside the U.S., and we remain on track to achieve our goal of delivering at least two billion doses to low- and middle-income countries by the end of 2022 — at least one billion to be delivered this year and one billion next year, with the possibility to increase those deliveries if more orders are placed by these countries for 2022. One billion of these doses will be supplied to the U.S. government at a not-for-profit price to be donated to the world’s poorest nations at no charge to those countries. Despite all we have been able to accomplish to date, we remain focused on our future, not our past.”
”Our ultimate goal is to help bring this pandemic to an end as quickly as possible, but also to apply the lessons we have learned through our work on the vaccine to all of our therapeutic areas. We look forward to providing future updates on these efforts,” he added.
*Pfizer, BioNTech vaccine
Pfizer Inc. Chart (1Y)
Shares of Pfizer are trading higher following the latest earnings beat, up by around 4% during the trading day on Tuesday. The stock is up by over 26% in the past year at $45.81 per share.
Pfizer is the 37th largest company in the world and 3rd largest pharmaceutical company, with a total market cap of $257.76 billion.
You can trade Pfizer Inc. (PFE) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD. Click here for more information. Trading Derivatives carries a high level of risk.
Sources: Pfizer, Visible Alpha, TradingView
Disclaimer: Articles are from GO Markets analysts and contributors and are based on their independent analysis or personal experiences. Views, opinions or trading styles expressed are their own, and should not be taken as either representative of or shared by GO Markets. Advice, if any, is of a ‘general’ nature and not based on your personal objectives, financial situation or needs. Consider how appropriate the advice, if any, is to your objectives, financial situation and needs, before acting on the advice. If the advice relates to acquiring a particular financial product, you should obtain and consider the Product Disclosure Statement (PDS) and Financial Services Guide (FSG) for that product before making any decisions.